Coronary stenting without pre-dilatation: an observational study

Conventional coronary stenting is done after pre-dilatation of the lesion. The bleeding complications and incidence of subacute stent thrombosis have been reduced significantly by the use of antiplatelet agents and high pressure balloon inflation to ensure complete stent expansion. Elective stenting also can be done without pre-dilatation by "stent alone technique." This approach significantly reduces the procedural cost and ischaemia time, avoiding potential complications such as abrupt vessel closure because of extensive dissection after conventional angioplasty and prior to stent deployment. Eighty patients of stable angina pectoris suitable for coronary angioplasty underwent stenting without pre-dilatation. Out of the 100 stents used, 38 were hand-crimped and 62 were pre-mounted. The target vessels were left anterior descending artery in 56 percent, right coronary artery in 32 percent and left circumflex in 12 percent. The procedure was successful in 88 percent lesions. In 12 percent stenting could be done only after pre-dilatation. In all these, there was proximal tortuosity and calcification. The fluoroscopy time was 10.2 +/- 4.5 minutes. The average number of balloons used per lesion was 1.08. Stent embolisation occurred in only one patient. There were no major adverse cardiac events in any of the patients. Thus stenting without pre-dilatation is safe. Patients who are eligible for stenting without pre-dilatation are those with stable angina pectoris without fluoroscopically visible calcium or coronary artery tortuosity and with lesions of moderate complexity.     

Right heart catheterization in acute lung injury: an observational study.

Right heart catheterization (RHC) is commonly used in the diagnosis and management of acute lung injury (ALI). However, controversy exists regarding RHC. We examined RHC use during the first 3 d of ALI in an observational study of 135 patients defined by American-European Consensus Conference criteria. Study parameters examined for association with RHC included the Acute Physiology and Chronic Health Evaluation (APACHE) III score, lung injury score (LIS), and 20 additional epidemiologic, clinical, and laboratory parameters. RHC was performed in 70 patients (52%) within the first 3 d of ALI. RHC was positively associated (p < 0.05) with a diagnosis of sepsis, APACHE III score, blood urea nitrogen (BUN), creatinine, net fluid balance, and positive end-expiratory pressure. RHC was negatively associated (p < 0.05) with mean arterial pressure (Pa) and PaO2/FIO2. Logistic regression identified four predictors for RHC placement: sepsis, PaO2/FIO2, BUN, and Pa. Initial right atrial and pulmonary artery occlusion pressure measurements demonstrated a moderately strong correlation (r = 0.72). Use of RHC was associated with a change in one or more therapeutic interventions (intravascular fluids, vasopressors, diuretics) in 78% of patients. In summary, patients receiving RHC during the first 3 d of ALI were more severely ill than those who did not receive RHC, and RHC was associated with a change in therapy in most patients.     

Clinical features of patients showing Candida hypersensitivity: an observational study.

BACKGROUND: The significance of Candida albicans as an allergen is still unclear. This study aimed at investigating the clinical features of patients monosensitized to Candida. METHODS: Thirty-four adult patients monosensitized to the yeast Candida albicans selected from a population of >7000 subjects and referred for suspect respiratory allergy were studied. Ninety subjects monosensitized to different airborne allergens served as controls. Both patients and controls underwent a clinical examination at the ENT department to detect possible nasal polyps. RESULTS: Male and female patients were equally distributed (17/17). The mean age of the patients was 58.4 years (range 23-75 years; median 59 years) vs 29.9 years (range 9-62 years) in controls (p <0.001). At baseline examination, 15 (44%) patients vs 5/90 (6%) controls were diagnosed as having nasal polyposis (p< 0.001). Polyposis was bilateral in 13/15 (87%) patients; 3 had "massive" polyps, and 4 had a clinical history of prior surgical intervention to remove nasal polyps. Eight patients (24%) had asthma, previously diagnosed as intrinsic in six cases. No patient had a history of aspirin-induced asthma (i.e. ASA triad). After one year 1/11 (9%) patients without polyps at the baseline examination had developed bilateral nasal polyposis. CONCLUSION: Candida-hypersensitivity is uncommon, occurs in older ages, and is strongly associated with nasal polyposis.     

Infliximab treatment in ankylosing spondylitis: an observational study

OBJECTIVE: To investigate efficacy, toxicity, and drug discontinuation in patients with ankylosing spondylitis (AS) treated with infliximab. METHODS: 35 patients with AS with mean (SD) age 42.5 (12.6) years and mean (SD) disease duration 14.5 (8.0) years were studied for 2 years. Patients entering the study had a negative tuberculin skin test, were fully informed about the treatment, and were followed up regularly. Infliximab, 5 mg/kg weight, was given intravenously at weeks 0, 2, 6, and every 8 weeks thereafter. Data concerning infliximab tolerability, adverse events, interval, and drug discontinuation were all recorded. Clinical improvement according to the BASDAI and the Ankylosing Spondylitis Assessment Study group (ASAS) 20%, 40%, and ASAS 5/6 response criteria were recorded. RESULTS: After 1 year, 20 (57%) patients achieved the BASDAI 50% response criteria, 25 (71%) achieved ASAS 20%, 23 (66%) reached ASAS 40%, and 18 (51%) attained ASAS 5/6. After 2 years' treatment, 11 (31%) patients achieved BASDAI 50% response criteria, 14 (40%) ASAS 20%, 11 (31%) ASAS 40%, and 9 (26%) ASAS 5/6. Clinical improvement was associated with an improved BASFI and reduction of CRP. After 2 years' treatment, "infliximab survival" was 89%. Treatment was well tolerated and adverse events were mild; 3 patients discontinued the study. CONCLUSION: Infliximab was effective, safe, and well tolerated in patients with AS.     

Epidemiology and economic burden of viral hepatitis: an observational population based study.

OBJECTIVE: To describe the epidemiology and estimate the health resource use of patients with viral hepatitis in Tayside, Scotland, using record linkage techniques. DESIGN: A retrospective observational study. SETTING: Liver disease database, Tayside, Scotland. PATIENTS: All subjects resident in Tayside in the study period 1989-1999 and registered on the Epidemiology of Liver Disease in Tayside (ELDIT) database. MAIN OUTCOME MEASURES: Incidence and prevalence of known viral hepatitis in Tayside, survival of subjects diagnosed with viral hepatitis, and the health resource use with respect to hospital admissions compared with the general population. RESULTS: There were 4992 patients identified with viral hepatitis in the study period 1989-1999; 86 were IgM positive anti-hepatitis A, 187 patients were hepatitis B surface antigen (HBsAg) positive, and 469 were anti-hepatitis C (HCV) positive. HCV and HBsAg seropositive patients were more likely to be hospitalised and stay in hospital longer, less likely to survive after six years, and used more drugs of potential abuse than the general population. There was an increase in cost per admission and per patient as a consequence of liver disease. CONCLUSIONS: A record linkage population based study of viral hepatitis allows outcomes to be identified and costed. Those at risk of viral hepatitis infection in the Tayside population should be informed about the future implication to their health and costs to society. The health service should investigate the cost effectiveness of vaccination and opportunity costs to the health service of viral hepatitis taking into consideration the increasing incidence and prevalence of disease.     

Continuous care in the treatment of obesity: an observational multicentre study

OBJECTIVES: To investigate weight loss and reasons for attrition in obese patients on long-term continuous care. DESIGN: Observational study with 36 months of follow-up. Setting. Fifteen Italian obesity centres applying a continuous care model of medical treatment. SUBJECTS: One thousand treatment-seeking obese subjects (785 females, median age 45.1 years, median BMI 37.4 kg m(-2)). Weight loss expectations were systematically recorded at baseline. INTERVENTIONS: An initial intensive treatment period (3-6 months) was followed by a less intensive continuous care (a follow-up control every 2-4 months). Main outcome measures. Attrition, reasons for treatment interruption and BMI change. Data were recorded by telephone interview in dropouts. RESULTS: Only 157 patients (15.7%) were in continuous treatment at 36 months. The main reasons of attrition were logistics, unsatisfactory results and lack of motivation. The only basal predictor for continuous care was lower Expected One-Year BMI Loss (P = 0.016). The probability of dropout increased systematically for any 5% expected BMI loss (Hazard ratio, 1.05; 96% confidence interval, 1.01-1.09). The mean percentage weight loss was greater in continuers (5.2% vs. 3.0% in dropouts; P = 0.016). However, the dropouts satisfied with the results or confident to lose additional weight without professional help reported a mean weight loss of 9.6% and 6.5% respectively. DISCUSSION: Continuous care produces long-term weight loss only in a subgroup of obese patients seeking treatment in medical centres. The finding that subgroups of dropouts report long-term weight loss has implication for the treatment of obesity.     

Cardiac findings of reactive arthritis: an observational echocardiographic study

The aim of this study was to assess echocardiographically the occurrence of cardiac abnormalities in patients with acute reactive arthritis (ReA). Eighteen consecutive adult patients with acute ReA were studied by the use of two-dimensionally guided M-mode and Doppler echocardiography. Aortic or mitral regurgitation were both detected in one of the patients. Mild to moderate left ventricular dilatation was observed in five patients, in four of whom the duration of acute ReA was over 6 months. In four patients, the ratio of peak early and peak late transmitral filling velocities was decreased. No patient had echocardiographic signs of myocarditis or pericardial effusion. In conclusion, no major structural cardiac alterations were detected. Mild valvular disease or mild to moderate left ventricular dilatation was observed in a quarter of the patients. Echocardiographic evaluation may be warranted if the acute ReA persists or has a prolonged course but is not recommended for routine use.     

Infliximab therapy in established rheumatoid arthritis: an observational study

PURPOSE: To investigate the efficacy, toxicity and drug discontinuation rate in an observational study of patients with established rheumatoid arthritis treated with infliximab. SUBJECTS AND METHODS: Between September 1999 and June 2003, we enrolled 84 patients with rheumatoid arthritis who were being treated with infliximab. All patients met the American College of Rheumatology criteria for rheumatoid arthritis and had been refractory to (or did not tolerate) at least two disease-modifying antirheumatic drugs. Patients entering the study had a negative purified protein derivative skin test, were fully informed about the treatment regimen, and were followed up at predefined times according to a standardized protocol. Data concerning infliximab dosage, tolerability, adverse events, concomitant therapy, dosage interval, and drug discontinuation were all recorded. In addition, the clinical and laboratory variables according to the American College of Rheumatology 20% and 50% response criteria and the disease activity score for the 28 joint indices were also recorded. RESULTS: There were 61 women and 23 men with a mean age of 59 +/- 8 years and mean disease duration of 11 +/- 6 years. Seventy-five percent (63/84) were seropositive for IgM rheumatoid factor. After the first year of treatment, 84.5% of patients continued to be treated with infliximab, whereas this percentage was 73% after the second year and 59% after the third year of treatment. The American College of Rheumatology 20% response criteria was met by 59/84 (70%) of patients, and 38/84 (45%) of the patients achieved the 50% response criteria in the first year of treatment. At the second year of therapy, the American College of Rheumatology 20% response criteria were reached by 35/84 (42%) of the patients and the 50% response criteria by 27/84 (32%). At the third year of treatment with infliximab, the American College of Rheumatology 20% and 50% response criteria were achieved by 13/84 (15.5%) and 10/84 (12%) of the patients, respectively. Twenty-eight of eighty-four (33%) patients discontinued infliximab therapy. The risk of drug discontinuation decreased with the concomitant use of methotrexate. The main reasons for drug discontinuation were adverse drug reactions (16/84, 19%), followed by lack of efficacy (9/84, 11%). The main reasons for drug discontinuation due to side effects were immediate hypersensitivity reactions (9/84, 11%) and infections (6/84, 7%). CONCLUSION: Infliximab was found to be an alternative treatment with a relatively acceptable toxicity profile, despite the fact that two patients developed pulmonary tuberculosis. After the third year of therapy, 59% of patients continued to be treated with infliximab. The concomitant use of methotrexate was associated with the continuation of infliximab therapy.     

Changing demographics in an HIV-infected population: results from an observational cohort study in Western Denmark.

We present demographic data from an observational database of HIV and AIDS in the Western part of Denmark, a region with a population of 2,935,156 individuals (55.1% of the population of Denmark). Five centers in the region treat HIV-positive adults; all patients attached to these centers since 1995 are included in this study. In total, 749 adult HIV-infected individuals were enrolled as of 31 December, 1999. Estimates of prevalence and incidence of HIV infection in the area were 25.9/100,000 and 2.6/100,000, respectively, which are lower than average for the country. The number of newly diagnosed HIV-infected patients remained constant during the period 1995-99, with an average of 62 diagnoses per year. The number of HIV-related deaths declined from 43 in 1995 to 15 in 1999. Of the enrolled patients, 70.9% were of Danish origin, 75% were Caucasians, 69.7% were male and 47.2% had heterosexual contact as their primary risk behavior. There seems to have been a shift in the HIV epidemic in recent years, with a higher proportion of newly diagnosed HIV patients having contracted the infection through heterosexual contact, a higher proportion being immigrants from less developed countries and newly diagnosed individuals getting older.     

Frequency of provision of CPAP in the inpatient setting: an observational study

Background

Little is known about the rates of provision of CPAP in inpatient settings. A single prior ??data mining?? study using diagnostic and procedural codes concluded that 6% of people with sleep apnea receive CPAP when in the hospital. The purpose of this study is to reexamine the frequency with which people who have an established diagnosis of sleep apnea receive therapy for it when they are admitted to the hospital for other reasons.

Methods

A retrospective cohort study of 195 people with an existing diagnosis of obstructive sleep apnea admitted to a tertiary medical center from March 2009?CJuly 2009. A logistic regression analysis was used to determine relative risk for provision of CPAP therapy controlling for the following variables: admission diagnosis, unit of admission (medical/surgical/psychiatric/pediatrics), length of stay, comorbidities, and patient characteristics (age/ race/ gender).

Results

Twenty-six percent of people with an established diagnosis of OSA received CPAP therapy during their hospitalization. In an additional 10%, therapy was offered but not implemented. Of the variables considered, only admission diagnosis of obesity (n?=?3) was associated with an increased likelihood of receiving CPAP.

Conclusions

This rate of provision of CPAP to hospitalized patients, while low at 26%, is much higher than a previous study on this topic that estimated frequency of use of CPAP strictly linking diagnostic codes for OSA and procedural codes for CPAP.